PHP
RVPH

Parkman Healthcare Partners’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Parkman Healthcare Partners’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,714
Closed -$931K – 102
2024
Q4 		$931K Buy
25,714
+104
+0.4% +$2.9K 0.12% 82
2024
Q3 		$738K Buy
25,610
+380
+2% +$8.44K 0.09% 88
2024
Q2 		$646K Buy
25,230
+37
+0.1% +$1.68K 0.09% 85
2024
Q1 		$1.9M Buy
+25,193
New +$2M 0.23% 86

Other funds holding RVPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Parkman Healthcare Partners's RVPH Position: Q1 2025 in Review

Parkman Healthcare Partners sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2025, closing a stake of 25,714 shares — an estimated $931K sold.

Parkman Healthcare Partners first reported a position in RVPH in Q1 2024 and held it in 4 quarters. The position peaked at $1.9M in Q1 2024. 48 funds tracked by Wall St. Rank hold RVPH as of Q1 2025.

  • Parkman Healthcare Partners reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 25,714 REVIVA PHARMA HLDGS INC shares in Q1 2025, an estimated $931K.
  • Parkman Healthcare Partners first reported a position in REVIVA PHARMA HLDGS INC in Q1 2024 and held it in 4 quarters.
  • Parkman Healthcare Partners's REVIVA PHARMA HLDGS INC position peaked at $1.9M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2025.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.